Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has been given a consensus rating of “Hold” by the twelve analysts that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $14.00.
Several research firms have commented on ZYNE. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $4.00 target price on shares of Zynerba Pharmaceuticals in a research note on Thursday, September 28th. Jefferies Group cut shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their target price for the stock from $12.00 to $7.00 in a research note on Tuesday, August 15th. HC Wainwright set a $7.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, August 15th. Maxim Group cut shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. Finally, Oppenheimer cut shares of Zynerba Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, August 14th.
In related news, major shareholder Michael Rapp acquired 25,745 shares of the stock in a transaction dated Monday, October 23rd. The stock was bought at an average cost of $9.94 per share, with a total value of $255,905.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 9.91% of the stock is owned by insiders.
Zynerba Pharmaceuticals (NASDAQ ZYNE) traded down $0.36 during mid-day trading on Thursday, reaching $13.01. 381,782 shares of the company’s stock traded hands, compared to its average volume of 641,867. Zynerba Pharmaceuticals has a 12-month low of $5.42 and a 12-month high of $25.95.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its earnings results on Tuesday, November 14th. The company reported ($0.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.05). During the same period in the previous year, the firm earned ($0.67) EPS. equities analysts anticipate that Zynerba Pharmaceuticals will post -2.49 earnings per share for the current fiscal year.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
What are top analysts saying about Zynerba Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zynerba Pharmaceuticals Inc. and related companies.